Evgen Pharma Share Discussion Threads

[moneymunch] 17/9/2020 15:18

Prof Albena Dinkova-Kostova project research website also updated;

Status Active

Effective start/end date

1/05/20 → 30/04/21

[moneymunch] 17/9/2020 15:08

James D Chalmers Retweeted
Open Research, University of Dundee
@UoD Open Research
·
Jul 16

#openaccess research

Can activation of #NRF2 be a strategy against COVID-19?

Rightwards arrow



@UoDMedicine
Prof Albena Dinkova-Kostova

#antiinflammatory #ARDS #KEAP1 #SARSCoV2 #sulforaphane

[moneymunch] 17/9/2020 15:03

James D Chalmers Retweeted
SULSA
@SULSAtweets
·
Aug 21

Today meet Prof Albena Dinkova-Kostova @UoDMedicine
, collaborating with @ProfJDChalmers
to study whether the anti-inflammatory Nrf2 activator sulforaphane can improve recovery and decrease the need for mechanical ventilation in patients with severe COVID-19 #ScotlandRespondsC19

[moneymunch] 17/9/2020 14:54

Ps Bumpa...start date 1/5/20....first patients expected to be administered in July...??? Gl:')

[moneymunch] 17/9/2020 14:39

Ps Bumpa, I've been checking the status of SFX-01's Covid-19 patient trials every minute near enough, and as soon as I get on the golf course....:')

Another game linedl up tomorrow but not until 12.30pm, and so expecting plenty of action!!!:')

[moneymunch] 17/9/2020 14:34

Lol Nobby....start date of SFX-01 Covid-19 patient trials 1st May 2020....maybe speculation on low death rates in Scotland throughtout July compared with previous months is connected...ho ho ho :-)

[bumpa33] 17/9/2020 10:10

Indeed Pogue, a veritable disaster.


Very happy to see us up and running though.

[pogue] 17/9/2020 09:55

Share price will go down now, 2 bits of good news in a week could ruin us.

[bumpa33] 17/9/2020 09:52

I’m assuming the start date listed as 1/5 is erroneous...?

[bumpa33] 17/9/2020 09:42

He gets a bit excited, I’m assuming he hasn’t been around long enough to be cynical - like the rest of us...

[nobbygnome] 17/9/2020 09:40

But I thought it was the reason deaths were so low in Scotland. Surely MM wasn't misleading us all?

[moneymunch] 16/9/2020 13:22

15/9/20

Rob Clarke’s Tweets
Rob Clarke
@RobClarkeLab
·

Very excited to be starting a new breast cancer research project on resistance to HER2-targeted therapy in partnership with @AACancerOrg
and @AndrewWardley
@OutreachRIGroup
@MCRBreastCentre

Action Against cancer

New Manchester partnership

Stopping breast cancer in its tracks, despite coronavirus

Coronavirus is disproportionately affecting cancer patients, whose immunity is low making them more susceptible to the virus. In addition, surgical treatment has had to be postponed for many. The pandemic has also understandably focused charitable spending towards tackling the direct impacts of the virus. However, cancer is not waiting for coronavirus to go away, and patients need support more than ever.

At Action Against Cancer, we have seen a marked drop in income in recent months due to the pandemic. Despite this we are determined to meet the commitments we had planned to fund life-saving research. This includes support for a new key priority project to be undertaken in partnership with The University of Manchester, the Manchester Breast Centre, the Outreach Research and Innovation Group and The Christie Hospital, one of the largest cancer treatment centres of its kind in Europe. We are delighted to announce this new partnership.

This innovative project aims to help patients with HER2+ type breast cancer whose tumours are not responding to treatment, by stopping their cancer in its tracks. Of the 55,200 or so new breast cancer cases diagnosed in the UK each year, more than 6,600 (12%) are HER2+.

Project objectives

Many patients diagnosed with breast cancer are given treatment to shrink a tumour as a first step, before the main treatment, which is usually surgery.

This initial treatment is called “neoadjuvant,” and whilst this is very helpful for some patients, unfortunately it does not work effectively in up to half of HER2+ breast cancer cases. This project aims to understand why this is, assess new drugs in lab models, and then with this knowledge design new clinical trials to test the effect of certain drugs with these patients to see what will work best.

Project outline

The team of scientists plan to analyse residual tumour samples from HER2+ breast cancer patients to discover the “signalling pathways” that remain active and drive the cancer. This can be thought of as similar to a train travelling to its destination through a number of stations. At most of the stations the signalling technology works flawlessly and there are no problems. However, if one signal has a fault, the train can go on the wrong track leading to tragedy.

A signalling pathway is a series of chemical reactions in which a group of molecules in a cell work together to control an outcome, for example cell division or cell death. After the first molecule in the pathway receives a signal, it activates another molecule, and so on until the cell function is carried out. Abnormal activation of signalling pathways can lead to cancer, and conversely, drugs targeting specific molecules in the pathway may help keep cancer cells from growing.

The three-year research project aims to identify the faulty signals and to design new clinical trials at The Christie to test drugs that would keep the patients health on track.

Project team

The team are ideally placed to do this research in terms of relevant expertise and access to key resources. The Manchester Cancer Research Centre Biobank has agreed to provide a wealth of the necessary samples to the team.

Professor Rob Clarke, Professor of Breast Biology at the University of Manchester

Professor Clarke’s team are highly experienced in generating the types of models of breast cancer as planned in this project.

Described by one of the scientific peer reviewers for this project as: “among the few scientists around that could tackle this challenge.”

Professor Andrew Wardley, Consultant in Medical Oncology and Medical Director of NIHR Manchester Christie Research Facility

Chair of the National Cancer Research Institute Breast Cancer Research Group.
Highly regarded Breast Medical Oncologist, treating patients and leading breast cancer trials at The Christie, in the UK and internationally for 19 years.
Clinical Director of the Christie hospital Early Phase Trials Unit since 2011.

Patients with treatment resistant HER2+ breast cancer are currently underserved with treatment options and their life prospects are too often bleak. Please support us to change this by donating to Action Against Cancer today.

[moneymunch] 16/9/2020 07:10

Perhaps one day we'll all be taking an analogue of SFX-01 to reverse or at least halt the aging process and/or protect us from multiple diseases......;-)

[moneymunch] 16/9/2020 07:06

Jim Mellon....Gla ;-)


Juvenescence Announces Licensing Agreement with Evgen Pharma plc
September 15, 2020 03:00 AM Eastern Daylight Time

DOUGLAS, Isle of Man--(BUSINESS WIRE)--Juvenescence Limited (“Juvenescence”), a life sciences company focused on modifying aging and increasing human healthspan, announced today a partnership with Evgen Pharma plc to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division. JuvLife will deploy Evgen’s Sulforadex® stabilization technology to create and manufacture a nutritional health supplement containing a defined and stable dose of sulforaphane, derived from natural sources.

Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies. It is focused on increasing how long people live in health by preventing the diseases of aging in the first place. JuvLife, one of several divisions within Juvenescence, is committed to be the trusted source of scientifically proven, branded health supplements and medical foods that help increase human healthspan and overall quality of life. The Juvenescence team includes highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in the pharmaceutical and consumer health sectors.

Colin Watts, Chief Executive Officer of JuvLife, said: “We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Sulforaphane is a well-studied natural metabolite derived from cruciferous vegetables that has been shown to activate NRF2 and act as a powerful inducer of the native antioxidant response, helping the body scavenge toxic metabolites and reducing markers of inflammation. In this agreement, we are licensing Evgen’s proprietary technology for the natural extraction and stabilisation of sulforaphane in a potent and cost-advantaged form that we believe is superior to all other sources currently commercially available. Juvenescence has built a reputation as a broad-based healthcare company in the longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen.’’

The license is for exclusive rights to leverage certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and Rest of World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales of the commercialized product.

Barry Clare, Executive Chairman of Evgen, said: “This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetization in an area which is outside our focus of therapeutic development in the NRF2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health supplements and brings in-depth experience in this sector. We are delighted to have them as a partner to bring the power of the sulforaphane platform to life in a non-pharmaceutical sector.”

[prharry] 15/9/2020 20:13

Weirdest day for positive news. They are funded now but with this deal they don’t need to be. Odd that shares are still stagnant

[bumpa33] 15/9/2020 19:55

hmm. Clear we had a seller in retrospect. Griffiths selling? He’s been offloading elsewhere.

[moneymunch] 15/9/2020 17:44

A few chunky late reported buys after close along with a 500k trade at 12.2p timed at 11.11am which looks like a sell, which probably put the spanner in the works on today's action...maybe the ex CEO parting with a few???...all in the mix regardless as we await further news on proceedings. Gla :-)

[lovewinshatelosses] 15/9/2020 16:44

Quite so, bumpa! :)

[bocker01] 15/9/2020 16:43

Well that’s a fairly rational view Nobby. It is an income stream but not huge. Most of these Pharma Co’s have no income stream and get hit periodically by share issues to cover funding. So whilst not a game changer, $10m over a couple of years may well offset future funding requirements and reduce one of the down sides. What did the last fund raising do? From memory it was £4m to cover us until this time next year. So I see it as very positive and a Further demonstration of the breadth of this company’s proposition As well as an indication that the management is thinking about leveraging that proposition. So all very good.

[bumpa33] 15/9/2020 16:40

Hmm, let’s be honest - not exactly the share price performance one would’ve hoped for.

God forbid they ever release “bad” news...!

[lovewinshatelosses] 15/9/2020 16:34

Thanks Nobby.

[nobbygnome] 15/9/2020 16:30

>> lovewinshatelosses

As timbo so eloquently described earlier there are some significant risks with this approach. However, it's an extra string to their bow with some upfront money which we didn't know about last week so must surely enhance the company value to some degree. But certainly not the 'game changer' some here are predicting on a regular basis.

Most definitely just a hold for me....

[moneymunch] 15/9/2020 16:26

Jim Mellon has just given Evgen £250k cash with potential milestones of £10.5m and royalties thereafter , I'll take that as a positive for Evgen's prospects but it's merely a small addition to Evgen's real Transformational upside potential ie a commercial JV with a Major pharma to advance and realise SFX-01's panacea and huge potential for multiple disease targets...Ker-Ching!!! :-)